Coxibs and NSAIDs - Is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007

Osteoarthritis and Cartilage

Volumn 15, Issue 8, 2007, Pages 849-856

  Moskowitz, R W ^a   Abramson, S B ^b   Berenbaum, F ^c   Simon, L S ^d   Hochberg, M ^e  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

^c HÔPITAL SAINT ANTOINE   (France)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Coxibs; NSAIDs; Osteoarthritis; Therapeutic approaches

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTICOAGULANT AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ESOMEPRAZOLE; ETORICOXIB; GLUCOCORTICOID; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PARECOXIB; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB; VALDECOXIB;

ADD ON THERAPY; BINDING COMPETITION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC PAIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONSENSUS DEVELOPMENT; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG USE; EDITORIAL; GASTRODUODENAL ULCER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART DEATH; HEART DISEASE; HEART INFARCTION; HUMAN; INFLAMMATION; LOW DRUG DOSE; MEDICAL INFORMATION; MONOTHERAPY; OSTEOARTHRITIS; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; STOMACH EROSION; STOMACH ULCER; THROMBOSIS; WORKSHOP;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; CYCLOOXYGENASE INHIBITORS; HUMANS; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 34547702866     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2007.06.012     Document Type: Editorial

References (61)

1. Moskowitz R.W., Abramson S.B., and Berenbaum F. Coxibs and NSAIDs-clearing the air. Osteoarthritis Cartilage 13 (2005) 545-547
2. Chou R., Helfand M., Peterson K., Dana T., and Roberts C. Comparative Effectiveness and Safety of Analgesics for Osteoarthritis. Comparative Effectiveness Review No. 4. (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-02-0024) (September 2006), Agency for Healthcare Research and Quality, Rockville, MD. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm
3. Wiesenhutter C.W., Boice J.A., Ko A., Sheldon E.A., Murphy F.T., Wittmer B.A., et al. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 80 (2005) 470-479
4. Bingham III C.O., Sebba A.I., Rubin B.R., Ruoff G.E., Kremer J., Bird S., et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology 46 (2007) 496-507
5. Berenbaum F., Grifka J., Brown J.P., Zacher J., Moore A., Krammer G., et al. Efficacy of lumiracoxib in osteoarthritis: a review of nine studies. J Int Med Res 33 (2005) 21-41
6. Gabriel S.E., Jaaklimainen L., and Bombadier C. Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs: a meta-analysis. Ann Intern Med 115 (1991) 787-796
7. Henry D., Lim L.L., Garcia-Rodriguez L.A., Perez Gutthann S., Carson J.L., Griffin M., et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 312 (1996) 1563-1566
8. Hernandez-Diaz S., and Garcia Rodriguez L.A. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. An overview of epidemiological studies published in the 1990s. Arch Intern Med 160 (2000) 2093-2099
9. Garcia Rodriguez L.A., and Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 12 (2001) 570-576
10. Richy F., Bruyere O., Ethgen O., Rabenda V., Bouvenot G., Audran M., et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 63 (2004) 759-766
11. Tarone R.E., Blot W.J., and McLaughlin J.K. Nonselective nonaspirin nonsterodial anti-inflammatory drugs and gastrointestinal bleeding: relative and absolute risk estimates from recent epidemiologic studies. Am J Ther 11 (2004) 17-25
12. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 284 (2000) 1247-1255
13. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
14. Schnitzer T.J., Burmester G.R., Mysler E., Hochberg M.C., Doherty M., Ehrsam E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
15. Laine L., Curtis S.P., Cryer B., Kaur A., Cannon C.P., and for the MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison. Lancet 369 (2007) 465-473
16. Goldstein J.L., Lowry S.C., Lanza F.L., Schwartz H.I., and Dodge W.E. The impact of low dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a nonselective nonsteroidal anti-inflammatory drug or cyclooxygenase 2 selective inhibitor. Aliment Pharmacol Ther 23 (2006) 1489-1498
17. Goldstein JL, Aisenberg J, Berger M, Dodge W. Effects of concomitant aspirin (81 mg qd) on incidence of gastric and/or duodenal ulcers in healthy subjects taking celecoxib or naproxen: a randomized, placebo-controlled trial. Poster #562. 5/23/2006. Digestive Disease Week, LA Convention Center, 502A.
18. Hooper L., Brown T.J., Elliott R.A., Payne K., Roberts C., and Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 329 (2004) 948
19. Brown T.J., Hooper L., Elliott R.A., Payne K., Webb R., Roberts C., et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modeling. Health Technol Assess 10 (2006) 1-183
20. Chan F.K., Hung L.C., Suen B.Y., Wu J.C., Lee K.C., Leung V.K., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 26 (2002) 2104-2110
21. Chan F.K., Wong V.W., Suen B.Y., Wu J.C., Ching J.Y., Hung L.C., et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 369 (2007) 1621-1626
22. FitzgGerald G.A. Coxibs and cardiovascular disease. N Engl J Med 351 (2004) 1709-1711
23. Strand V., and Hochberg M.C. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum 47 (2002) 349-355
24. White W.B., West C.R., Borer J.S., Gorelick P.B., Lavange L., Pan S.X., et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 99 (2007) 91-98
25. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102 (Published correction appears in N Engl J Med 2006;355:221)
26. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
27. Solomon S.D., Pfeffer M.A., McMurray J.J., Fowler R., Finn P., Bernard L., et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114 (2006) 1028-1035
28. Nussmeier N.A., Whelton A.A., Brown M.T., Langford R.M., Hoeft A., Parlow J.L., et al. Complications of the Cox-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 1081-1091
29. Catella-Lawson F., Reilly M.P., Kapoor S.C., Cucchiara A.J., DeMarco S., and Tourmier B. Cyclooxygenase inhibitors and the antiplatelet effect of aspirin. N Engl J Med 345 (2001) 1809-1817
30. MacDonald T.M., and Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361 (2003) 573-574
31. Farkouh M.E., Greenberg J.D., Jeger R.V., Ramanathan K., Verheugt F.W., Cheseboro J.H., et al. Cardiovascular outcomes in high-risk patients with osteoarthritis treated with ibuprofen, naproxen, or lumiracoxib. Ann Rheum Dis (2007) (Epub ahead of print)
32. Cannon C.P., Curtis S.P., FitzGerald G.A., Krum H., Kaur A., Bolognese J.A., et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison. Lancet 368 (2006) 1771-1781
33. Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., and Patrano C. Do selective COX-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ 332 (2006) 1302-1308
34. Ray W.A., Stein C.M., Hall K., Daugherty J.R., and Griffin M.R. Nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 359 (2002) 118-123
35. Solomon D.H., Schneeweiss S., Glynn R.J., Kiyota Y., Levin R., Mogun H., et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109 (2004) 2068-2073
36. Graham D.J., Campen D., Hui R., Spence M., Cheetham C., Levy G., et al. Risk of acute myocardial infarction and sudden cardiac death associated with use of COX-2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 (2005) 475-481
37. Singh G., Mithal A., and Triadafilopoulos G. Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient, not the drug class. Ann Rheum Dis 64 (2005) S85-S86
38. Hernandez-Diaz S., Varas-Lorenzo C., and Garcia Rodriguez L.A. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 98 (2006) 266-274
39. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of observational studies of selective and nonselective cyclooxygenase 2. JAMA 296 (2006) 1633-1644
40. Patrono C., Ciabattoni G., Pugliese F., Pierucci A., Blair I.A., FitzGerald G.A., et al. Estimated rate of thromboxane secretion into the circulation of normal men. J Clin Invest 77 (1986) 590-594
41. Singh G., Graham D., Wang H., Mithal A., and Triadafilopoulos G. Concomitant aspirin use reduces the risk of acute myocardial infarction in users of cyclooxygenase-2 selective and some non-selective nonsteroidal anti-inflammatory drugs. Ann Rheum Dis 65 (2006) S61
42. Whelton A., Fort J.G., Puma J.A., Normandin D., Bello A.E., Verburg K.M., et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 8 (2001) 85-95 Erratum in Am J Ther 2001;8:220
43. Whelton A., White W.B., Bello A.E., Puma J.A., and Fort J.G. SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥ 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 90 (2002) 959-963
44. Pope J.E., Anderson J.J., and Felson D.T. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Ann Intern Med 153 (1993) 477-484
45. Chenevard R., Hurlimann D., Bechir M., Enseleit F., Spieker L., Hermann L., et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107 (2003) 405-409
46. Widlansky M.E., Price D.T., Gokce N., Eberhardt R.T., Duffy S.J., Holbrook M., et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 107 (2003) 310-315
47. Hermann M., Camici G., Fratton A., Hurlimann D., Tanner F.C., Hellerman J.P., et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 108 (2003) 2308-2311
48. Altman R.D., Hochberg M.C., Moskowitz R.W., and Schnitzer T.J. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 43 (2000) 1905-1915
49. Simon L.S., Lipman A.J., Caudill-Slosberg M., Gill L., Keefe F.L., Kerr K.L., et al. Guidelines for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis (2002), American Pain Society, Glenview, IL (pp. 1-178)
50. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W.J., Dieppe P., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62 (2003) 1145-1155
51. Zhang W., Doherty M., Arden N., Bannworth B., Bijlsma J., Gunther K.-P., et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 64 (2005) 669-681
52. Chan A.T., Manson J.E., Albert C.M., Chae C.U., Rexrode K.M., Curhan G.C., et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 113 (2006) 1578-1587
53. Forman J.P., Rimm E.B., and Curhan G.C. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 167 (2007) 394-399
54. Dedier J., Stampfer M.J., Hankinson S.E., Willett W.C., Speizer F.E., and Curhan G.C. Non-narcotic analgesic use and risk of hypertension in US women. Hypertension 40 (2002) 604-608
55. Green K., Drvota V., and Vesterquist O. Pronounced reduction in prostaglandin synthesis in humans by acetaminophen (paracetamol). Prostaglandins 37 (1989) 311-315
56. Kurth T., Glynn R.G., Walker A.M., Chan K.A., Buring J.E., Hennekens C.H., et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 108 (2003) 1191-1195
57. Kimmel S.E., Berlin J.A., Reilly M., Jaskowiak J., Kishel L., Chittams J., et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 43 (2004) 985-990
58. Curtis J.P., Wang Y.-F., Portnay E.L., Masoudi F.A., Havranek E.P., and Krumholz H.M. Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ 327 (2003) 1322
59. Laine L., Smith R., Min K., Chen C., and Dubois R.W. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 24 (2006) 751-767 (Review)
60. Tannenbaum H., Bombardier C., Davis P., and Russell A.S. Third Canadian Consensus Conference Group. An evidence-based approach to prescribing nonsteroidal anti-inflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 33 (2006) 140-157
61. Antman E.M., Bennett J.S., Daugherty A., Furberg C., Roberts H., Taubert K.A., et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115 (2007) 1634-1642